MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
Rhea-AI Summary
MannKind (Nasdaq: MNKD) has scheduled its third quarter 2024 financial results release for Thursday, November 7, 2024, after market close. The company will host a webcast at 4:30 p.m. Eastern Time to discuss quarterly results and provide a business update. CEO Michael Castagna and CFO Chris Prentiss will lead the conference call. The webcast will be available on MannKind's investor relations website, with a replay accessible for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – MNKD
On the day this news was published, MNKD gained 1.41%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024.
MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the quarterly results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
For MannKind:
Investor Relations
Ana Kapor
(818) 661-5000
Email: ir@mnkd.com
Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
FAQ
When will MannKind (MNKD) release Q3 2024 earnings?
What time is MannKind's (MNKD) Q3 2024 earnings call?
How can I access MannKind's (MNKD) Q3 2024 earnings call?
How long will MannKind's (MNKD) Q3 2024 earnings call replay be available?
